Vaccine Discoveries Drive India’s Biotech Industry (India)
This article was originally published in PharmAsia News
Executive Summary
India's biotechnology companies count on the vaccines end of their business to drive the rest of their work in developing therapeutics, diagnostics and other segments. The vaccines segment accounts for more than 70 percent of biotech work in the country, increasing at a rate of more than 30 percent a year, reaching the $3 billion mark by 2010. The biotechs rely heavily on public institutions to do early-stage research, such as producing cell lines, so the companies can focus on process and clinical development. That trend was begun by Shantha Biotechnic's work in developing a hepatitis B vaccine based on earlier work by the Centre for Cellular and Molecular Biology. (Click here for more
You may also be interested in...
QUOTED. 5 August 2020. Eric Fanning.
AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.
Warp Speed Lives Up To Its Name: FDA Planning Late October Vaccine Advisory Committee
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.
Ahead Of Ryoncil’s Advisory Committee, Citizen Petition Opposes Approval For Pediatric GVHD
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Need a specific report? 1000+ reports available
Buy Reports